Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the treatment of anemia in patients with chronic kidney disease CKD who are on hemodialysis. This Phase III, investigator-blinded, randomized, multicenter study compares two drugs, efepoetin alfa and darbepoetin alfa, to see how well they maintain hemoglobin levels in these patients. The study aims to maintain hemoglobin between 10.0 gdL and 12.0 gdL, which is important for managing anemia in CKD. Participants will be randomly assigned in a 21 ratio to receive either efepoetin alfa or darbepoetin alfa. Both drugs are given by intravenous injection, typically after dialysis sessions. Efepoetin alfa is administered weekly from Day 1 to Week 28, with possible interval changes to one or two weeks from Week 29 to Week 52 based on investigator judgment. The study consists of three periods screening up to 28 days, treatment about 52 weeks, and a 4-week follow-up with phone contacts up to Week 56 or the last visit. During the study, participants will undergo regular assessments including hemoglobin level monitoring to evaluate the mean change between Week 20 and Week 28. Safety and efficacy are closely observed, with dosages adjusted to maintain target hemoglobin levels. Follow-up will include phone contacts to monitor participants up to Week 56. The total participation duration is approximately one year, starting from screening through treatment and follow-up.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are conducting a national, prospective, multicenter observational pilot project in the Czech Republic to screen for Chronic Thromboembolic Pulmonary Hypertension CTEPH in patients who have experienced Acute Pulmonary Embolism APE. The study aims to develop and evaluate a standardized early detection procedure to improve patient outcomes and ensure cost-effective healthcare. This project involves multiple centers and targets patients after APE to facilitate timely diagnosis and treatment referral. Participants who have had APE will undergo a standardized screening protocol for early identification of CTEPH. If there is a risk identified during screening, patients will be referred promptly to specialized pulmonary hypertension centers for further management. This process includes implementing and testing a uniform screening algorithm and ensuring efficient patient flow from cardiologists to specialized treatment centers. During the study, participants will be assessed using this screening process within six months of enrollment. Key outcomes include the positive predictive value of the initial examination, rates of CTEPH detection, and the proportion of suspected cases attending follow-up at specialized centers. The study will monitor these factors to validate the screening protocols effectiveness and impact on patient care, with follow-up continuing up to six months after enrollment.
Actively Recruiting
This research focuses on following up with 5-year-old children who were born prematurely to develop and test a national approach for their care. The goal is to reduce the negative effects on the childs overall development and support their families by creating a standardized method for long-term monitoring of developmental abnormalities in these children. Children in the study undergo a detailed pediatric check-up that includes vision screening, speech and language tests, psychological evaluation, motor skills assessment, and lung function testing. If any issues are found during these assessments, children are referred to specialists such as rehabilitation doctors, speech therapists, psychiatrists, or ophthalmologists. This pilot project involves multiple centers and aims to validate this screening process for 210 children. Participants will receive comprehensive evaluations during the study visit lasting up to three days. Researchers will measure how many children have identified developmental problems and how many require referral to specialized care. This timely check-up is important for both the childs health and family support. The project is expected to complete by August 2027.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of subcutaneous treatment with lunsekimig compared with placebo in adults aged 40 to 80 years who have inadequately controlled Chronic Obstructive Pulmonary Disease COPD characterized by an eosinophilic phenotype. This Phase 2bPhase 3 study includes participants with a history of COPD, ongoing symptoms despite treatment, and specific lung function and blood eosinophil criteria. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a placebo group. All treatments are given as subcutaneous injections during a 48-week treatment period. The study consists of a screening period up to 4 weeks, followed by the 48-week randomized treatment, and then an approximately 8-week follow-up period, totaling up to 60 weeks of participation. During the study, participants will undergo lung function tests, symptom and quality of life questionnaires, and blood tests to monitor eosinophil counts and drug levels. The main outcome measured is the annualized rate of moderate-to-severe COPD exacerbations over 48 weeks. Additional assessments include changes in lung function, symptom scores, safety events, and antibody development. Safety monitoring continues through the follow-up period after treatment ends.